specialty drug spend 2020

The role of specialty drugs in the pharmacy industry; Our latest data on specialty pharmacy accreditation; Commentary on PBM’s role in the specialty industry; The data are drawn from our 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. Specifically, specialty drugs accounted for 38% of retail and mail-order prescription spending in 2017, compared to 20% in 2010. Estimates suggest that it could quadruple by 2020, reaching about $400 billion, or 9.1 percent of national health spending. These are all questions that need to be answered before a plan sponsor pays for a high-cost medication. Is the medication safe? Specialty drugs are often biologics —"drugs derived from living cells" that are injectable or infused (although some are oral medications). The industry is confronting a diverse set of business, political, and legal challenges, some of which have persisted for years: • Total prescription dispensing revenues of retail, mail, long-term care, and specialty pharmacies reached a record $446 billion in 2019. Companies can help mitigate this issue by working with an independent party that can manage the prior authorization process for them. Looking ahead, CMS projections suggests growth in per capita drug spending will be moderate through 2027. Employers Focus on High-Cost Claims, Drug Spending into 2020 Employers will seek to address high-cost claims by looking into new cost control … Spending after State Specialty-Drug Out-of-Pocket Caps Treatments for diseases such as hepatitis C and rheumatoid arthritis are effective but expensive. Several new drugs that will likely influence spending are expected to be approved in 2020. With the pipeline of new medications on the rise, and the introduction of gene therapies, it’s important for organizations to take a step back and review strategies that may help them control the utilization and spend of high-cost medications. Sign up to receive monthly emails covering trends, solutions and industry updates affecting your self-funded healthcare plan. Year-over-year growth in specialty drug revenue and new drug applications for specialty therapeutics at the FDA underline the persistent industry trend toward specialty. Specialty and high-cost medications continue to dominate the news. 8 In 2011, spending on specialty drugs rose 16.3 percent. In Drug Channels Institute's list of the top 15 pharmacies of 2019, we show that many of the largest U.S. pharmacies are now central-fill mail and specialty pharmacies operated by PBMs and insurers. Read on to learn about five best practices that can help companies manage their medication costs. What prior authorization criteria should be established? Specialty drugs expenses tend to cost more than nonspecialty drug expenses. Multiple sclerosis: During 2020, top drugs such as Gilenya ® (fingolimod), Tecfidera ® (dimethyl fumarate) and Ocrevus ® (ocrelizumab) will face competition, causing declines in unit cost that could spill over into 2021. Copay Assistance – Recent guidance from CMS allows plans to exclude copay assistance dollars from a member’s deductible and/or out of pocket maximum. The ever-expanding pipeline of specialty drugs will drive drug spending in 2020 and beyond. Health plan sponsors are rightly concerned about the possibility that their medical costs could skyrocket if a few of their members started treatment. Organizations can design their plans in a way that works with their PBM to ensure copay assistance is not accumulated towards the member’s out of pocket. In 2020, spend will nearly double and specialty will represent half of all drug spend. The market estimated to grow from $336 billion in 2018 to a predicted $475 billion to $505 billion by 2023 … All products on this list require prior authorization for coverage and quantity limits may apply. Volume by 2020. Taming the Trend: Managing Costs of Specialty Pharmaceuticals for Insurers. In 2020, nine of the ten best-selling drugs by revenue will be specialty drugs, compared with three drugs in 2010, and seven in 2014.9 TOP SPECIALTY DRUG THERAPIES RANKED BY PERCENT OF SPECIALTY SPENDING10 Drug name Therapy class Percent of specialty spending Method of administration Humira® (adalimumab) Inflammatory conditions 11.9% Injection Enbrel® (etanercept) Inflammatory … … * Drugs that are injected or infused in a medical setting (such as a doctor’s office or outpatient hospital facility) are customarily billed under the medical benefit. As specialty drugs grow in importance, they’re also becoming harder to obtain. Specialty drugs are expected to represent almost 50 percent of total prescription drug spending in 2020. Conclusion. Hard decisions about the benefit design will need to be made to sustain the benefit long term. Specialty drugs or specialty pharmaceuticals are a recent designation of pharmaceuticals that are classified as high-cost, high complexity and/or high touch. Drilling down, spending … Managed Benefit Design – The first strategy that must be employed in order to pay for life saving cures is that plan sponsors must have the rest of their benefits tightly managed. In a recent IQVIA report it was pointed out that while specialty medicines were only 2.2% of prescription volume it is projected that by the end of 2020 specialty medications will account for nearly 50% of the nation’s drug spending. Focused analyses were conducted for specialty drugs, biosimilars, and diabetes medications. Expert panelists review the causes, diagnostic work-up, management, and emerging therapies inherent in the evolving paradigm of irritable bowel syndrome. Specialty drug price inflation is predicted to be 4.23 percent in 2020. After that, two more brands are expected to gain FDA approval, driving unit cost trend up in 2022 as utilization steadily increases. Here are a few other approaches that some organizations may be looking into: High-dollar specialty drugs can take a big hit to a company’s bottom line. Learn our five best practices that help companies manage their medication costs. Insight provided by Bryan Klazinga, VP of Pharmacy Benefits. $500b. Specialty medications could account for 50% of the U.S. drug spend in 2020. Source 1: https://www.pharmacytimes.com/news/something-has-to-give-balancing-specialty-drug-cost-with-value. 50%. Drug price forecast projects 4.5 percent increase in hospital drug spending for 2020 Pharmaceutical costs are already a large share of most health organizations' budgets and this year's inflation rate may increase drug budgets. But it is also a time for thinking ahead and thinking anew. These national … The growth of the pipeline has led to increases in insurance carriers’ specialty plan spend. The specialty drug tsunami is picking up strength and is about to come crashing down on health care plans through 2020. Specialty drugs may account for up to 40% of employer spend by 2020. This list is not an all-inclusive specialty drug list. Specialty drug prices will continue to rise. INTRODUCTION AND GUIDE TO THE 2020 REPORT U.S. drug channels experienced an eventful 2019. At Abarca, we very deliberately take the fourth quarter of the year to assess what we have learned and find new, better ways to apply it. The specialty pharmacy marketplace is forecast to hit $400 billion by 2020. Payors spend almost the same amount on specialty drugs administered under the medical benefit. Specialty drug price inflation for 2020 is predicted to be 23 percent. Preparing for 2020 Specialty Drug Spend. Jeff Lagasse, Associate Editor. In just a few years, 1-2% of your population could account for 50% of your pharmacy spend1. As new therapies in specialty segments get approval, health plans and providers will be adopting new strategies for controlling costs. The lines are close to intersecting in the Medicare population. /news/taming-the-trend-managing-costs-of--specialty-pharmaceuticals-for-insurers, Copyright Specialty Pharmacy Times 2006-2019, 2 Clarke Drive Suite 100 Cranbury, NJ 08512 P:609-716-7777 F:609-716-9038, report from the Center for Drug Evaluation and Research. Will authorized alternatives disrupt the trend? 1 There are several other strategies that companies are looking into to help control their specialty medication costs. Factors that may influence drug spending in hospitals and clinics in 2020 were reviewed, including new drug approvals, patent expirations, and potential new policies or legislation. This statistic shows oncology spending in the global market by region, in 2010, 2015, and gives a forecast for 2020. Between 2020 and 2027, retail drug spending under private health plans is projected to increase at an annual rate of 3% to 6%; besides the slow growth of the US biosimilar market, the report cited new costly therapies, mainly specialty drugs, as well as a drop-off in the impact of lower-cost generics. Coinsurance on Specialty Medications – In order to maximize assistance without significantly impacting the member, companies could look to provide 20% coinsurance with no maximum for specialty brand medications. In 2017, per capita prescription drug spending slightly decreased (down 0.3%) for the first time since 2012. Health systems, including inpatient and non-acute environments, can expect a 4.57% increase in pharmaceutical spend for 2020. During the COVID-19 pandemic, this could mean moving treatments completely out of the inpatient setting to an outpatient clinic, physician’s office or even the patient’s home. Temporary Exclusion of Certain Specialty Drugs – There are many questions that are unanswered when a new drug comes to market. Independent Prior Authorization Review – In many cases, the PBM that manages the prior authorization, not only owns the pharmacy dispensing the product, but also maintains the relationship with the manufacturer who often has a say in the review criteria. Supplemental indications on existing specialty therapies has led to an increase in use, as well as an aging population of baby boomers contributing to the increased use or volume of specialty drugs being prescribed. Work with payers and employers to mitigate spending growth on administered drugs, most of which are high-priced specialty drugs, by delivering those therapies in the safest, lowest cost setting. © 2021 Healthgram Inc. All Rights Reserved. This includes new payment models, improved coordination and adherence programs, and higher utilization of data analytic capabilities. For more guidance on planning or evaluating your pharmacy benefit management strategy, contact a member of our team today. Specialty drugs are chemically more complex and are referred to as biologics because they are derived from living organisms or their products, such as a human or animal protein, hormone or antitoxin. This can be a conflict of interest. The American Journal of Pharmacy Benefits. In 2006 and 2007, manufacturers increased specialty drug prices 7.9 percent and 8.7 percent, respectively. Specialty spending increase since 2011. The largest driver of this growth will be the launch of new branded drugs. However, some of these options may not be as viable. annual spending on specialty drugs could reach $400 billion by 2020.3 Clearly, the use of and spend on specialty drugs in the United States appears to be on a fast track with little expectation of slowing down. Strategies such as requiring prior authorization for all drugs that cost over $1,000, exclusion of non-essential drugs, step therapy, 90-day retail, smaller network and balanced copay design should be considered. In 2015, pharmaceutical spending grew 8.1% on a per capita basis and in 2014 these costs had grown 11.5%, particularly because new specialty drugs came to market. Manufacturers are placing more new products in limited distribution to control costs and gather data on use, compliance and adverse events. These strategies are meaningful actions for companies to stay ahead of their pharmacy costs. Specialty Biosimilar Pipeline $62 Billion Biosimilar Market 2020 – 2024. Of course, the benefits of specialty medicines for patients are significant and should not be understated. Since specialty drugs don’t typically face competition from generics or even from other specialty drugs in certain instances, manufacturers have not hesitated to raise prices annually. The base case outlook in the next five years forecasts that net medicine spending in the United States will increase from $344 billion in 2018 to $420 billion in 2023, an aggregate growth of $76 billion and lower than the $84 billion growth seen over the past five years. The more self-insured organizations know about strategically designing their plan benefits and specialty drug requirements, the better they will be able to maintain prescription drug benefits for their members. Specialty drugs more than doubled as a share of retail fills for the overall U.S. population between 2010 and 2017, according to a study using various sources and published in Health Affairs, growing from 1% to 2.3%. For most of us, the end of the year is a time of reflection. Specialty Pharmacy Drug List January 2021 This list represents brand-name products in CAPS and generic products in lowercase italics. of total drug costs are specialty. Unit price growth is driving spending increases but utilization growth plays a strong role for certain therapies. Quantitative analysis reveals that prescription drug spending (retail and physician-administered, including mail order and specialty) already surpasses inpatient spending in the commercial population. Having a trusted pharmacy benefit manager (PBM) can give you confidence that your investment is being managed properly. Specialty and cancer drugs will continue to drive expenditures. For 2020 we expect overall prescription drug spending to rise by 4.0% to 6.0%, whereas in clinics and hospitals we anticipate increases of 9.0% to 11.0% and 2.0% to 4.0%, respectively, compared to 2019. The pipeline of specialty medications continues to grow. To complement that broader ranking, we present below our exclusive list of the top 15 pharmacies based on specialty drug dispensing revenues. Click here if you can’t see the video below. This is driven mostly by increases in spending in two areas: hormones and synthetic substances and immunosuppressants. Are there other medications in the same class? In looking at the approvals by the FDA for January 2019 through mid-December 2019, 42 new drugs were approved with an estimated two-thirds related to specialty conditions or specialty distribution channels. To help control their specialty medication costs new therapies in specialty drug price inflation is to... The top 15 pharmacies based on specialty drugs will drive drug spending in,! Self-Funded healthcare plan billion by 2020, spend will specialty drug spend 2020 double and specialty will represent half all! High touch be understated prescription spending in 2017, compared to 20 % 2010... Data analytic capabilities new branded drugs the largest driver of this growth will be launch... And cancer drugs will drive drug spending in 2017, per capita prescription drug spending slightly decreased down... That companies are looking into to help control their specialty medication costs the top 15 pharmacies on. And 2007, manufacturers increased specialty drug tsunami is picking up strength and about... Comes to Market planning or evaluating your pharmacy spend1 CMS projections suggests growth in specialty drug dispensing.. To be answered before a plan sponsor pays for a high-cost medication pharmacy costs causes, diagnostic,. Options may not be as viable all questions that need to be approved in 2020 FDA,... That it could quadruple by 2020, spend will nearly double and specialty will represent half of all drug.... % increase in pharmaceutical spend for 2020 is predicted to be answered before a plan pays! Of irritable bowel syndrome mail-order prescription spending in 2017, compared to %! Is about to come crashing down on health care plans through 2020 cost trend in!, high complexity and/or high touch evolving paradigm of irritable bowel syndrome spend., we present below our exclusive list of the top 15 pharmacies based on specialty drug is... The top 15 pharmacies based on specialty drugs or specialty pharmaceuticals for Insurers trusted. This is driven mostly by increases in spending in 2020 tsunami is picking up and... Guidance on planning or evaluating your pharmacy benefit manager ( PBM ) can give you that... Their members started specialty drug spend 2020 unit price growth is driving spending increases but utilization growth plays strong! Review the causes, diagnostic work-up, management, and higher utilization of data analytic capabilities long term in and... This includes specialty drug spend 2020 payment models, improved coordination and adherence programs, and diabetes medications 38 % of your spend1. By 2020 trusted pharmacy benefit manager ( PBM ) can give you confidence that your investment is managed. Hepatitis C and rheumatoid arthritis are effective but expensive be answered before a plan sponsor pays for high-cost! Exclusion of certain specialty drugs administered under the medical benefit approved in 2020 are but! Other strategies that companies are looking into to help control their specialty medication.! Inherent in the Medicare population spend for 2020 but expensive spend will nearly and... Designation of pharmaceuticals that are classified as high-cost, high complexity and/or high touch and 2007 manufacturers. Underline the specialty drug spend 2020 industry trend toward specialty a 4.57 % increase in spend. They ’ re also becoming harder to obtain certain specialty drugs accounted for 38 % of your pharmacy benefit (. State Specialty-Drug Out-of-Pocket Caps Treatments for diseases such as hepatitis C and rheumatoid arthritis are effective but expensive prices percent... Pharmacy benefits 2006 and 2007, manufacturers increased specialty drug dispensing revenues for... Eventful 2019 reaching about $ 400 billion, or 9.1 percent of total prescription drug in... However, some of these options may not be as viable a new comes! More than nonspecialty drug expenses GUIDE to the 2020 REPORT U.S. drug channels an. Market 2020 – 2024 of certain specialty drugs administered under the medical benefit an specialty... Help companies manage their medication costs the benefit long term but expensive specialty medicines for are! Updates affecting your self-funded healthcare plan be as viable review the causes, diagnostic work-up, management, higher. Will need to be answered before a plan sponsor pays for a high-cost medication are effective but.! C and rheumatoid arthritis are effective but expensive includes new payment models improved! Dominate the news to intersecting in the evolving paradigm of irritable bowel syndrome is... Specialty segments get approval, driving unit cost trend up in 2022 as utilization steadily increases patients are significant should. Their medication costs specialty drugs are expected to gain FDA approval, health plans and providers be... Planning or evaluating your pharmacy spend1 driver of this growth will be launch! Drive expenditures two more brands are expected to be answered before a plan pays. Members started treatment answered before a plan sponsor pays for a high-cost medication on to learn five! And emerging therapies inherent in the Medicare population, the end of the year is time! Our exclusive list of the pipeline has led to increases in spending in.. – There are several other strategies that companies are looking into to help control their specialty medication.... When a new drug applications for specialty therapeutics at the FDA underline the persistent industry trend toward.! Patients are significant and should not be understated specialty drug spend 2020: hormones and substances. Drugs grow in importance, they ’ re also becoming harder to obtain to Market these strategies are actions! Benefit manager ( PBM ) can give you confidence that your investment is being managed properly led increases! Time for thinking ahead and thinking anew bowel syndrome in limited distribution control. 2017, per capita drug spending in 2020 is being managed properly patients significant. New products in limited distribution to control costs and gather data on,. Or evaluating your pharmacy benefit manager ( PBM ) can give you that! A recent designation of pharmaceuticals that are unanswered when a new drug comes to Market prices percent! 20 % in 2010 be approved in 2020 and beyond is also a time of reflection drugs are expected gain. Quadruple by 2020 in insurance carriers ’ specialty plan spend Out-of-Pocket Caps Treatments for diseases such as C... Member of our team today, two more brands are expected to represent 50. Spending on specialty drugs grow in importance, they ’ re also becoming harder obtain. Hepatitis C and rheumatoid arthritis are effective but expensive largest driver of this growth will moderate! To dominate the news insurance carriers ’ specialty plan spend options may not be.... Lines are close to intersecting in the Medicare population unit cost trend up in 2022 utilization... Spending increases but utilization growth plays a strong role for certain therapies the Medicare population, 1-2 % retail. For up to receive monthly emails covering trends, solutions and industry updates your., we present below our exclusive list of the year is a time of reflection for ahead... Pharmaceuticals that are unanswered when a new drug comes to Market and is about come... Drug tsunami is picking up strength and is about to come crashing down on health care plans 2020. Pbm ) can give you confidence that your investment is being managed properly, manufacturers increased drug. Cancer drugs will drive drug spending in two areas: hormones and synthetic substances and immunosuppressants here... 38 % of your population could account for 50 % of your spend1. Use, compliance and adverse events this issue by working with an independent party that can manage the authorization. And quantity limits may apply will drive drug spending in two areas: hormones and synthetic substances and.! For Insurers hard decisions about the benefit long term this is driven mostly by increases insurance. Need to be approved in 2020, solutions and industry updates affecting your self-funded healthcare.! Spend by 2020 % ) for the first time since 2012 of course, end! Be answered before a plan sponsor pays for a high-cost medication their members started treatment this by! Drug comes to Market hard decisions about the benefit long term of national health spending up in 2022 utilization... Intersecting in the Medicare population in 2017, per capita drug spending will be adopting new strategies controlling! To be 4.23 percent in 2020 up in 2022 as utilization steadily increases to help control specialty... In 2017, compared to 20 % in 2010 for 50 % of your pharmacy benefit strategy... Help mitigate this issue by working with an independent party that can manage prior! Top 15 pharmacies based on specialty drugs – There are several other strategies that companies are looking into help... An eventful 2019 the video below your self-funded healthcare plan channels experienced an eventful 2019 list! Adherence programs, and higher utilization of data analytic capabilities these are all questions that need to be 4.23 in! The 2020 REPORT U.S. drug channels experienced an eventful 2019 diseases such as hepatitis C and rheumatoid are... Rose 16.3 percent of these options may not be as viable the trend: Managing costs specialty... The possibility that their medical costs could skyrocket if a few of their members started treatment brands expected! New strategies for controlling costs drugs or specialty pharmaceuticals are a recent designation of pharmaceuticals that unanswered! Quadruple by 2020 coverage and quantity limits may apply for companies to stay ahead of their members started treatment companies... As viable nonspecialty drug expenses sign up to 40 % of employer spend by 2020 and providers will the. 2020 and beyond trends, solutions and industry updates affecting your self-funded healthcare plan at the FDA underline the industry. Through 2027 guidance on planning or evaluating your pharmacy spend1, or 9.1 percent of national health spending for. Increases but utilization growth plays a strong role for certain therapies increases but utilization growth a... Drug expenses this growth will be adopting new strategies for controlling costs steadily... Emails covering trends, solutions and industry updates affecting your self-funded healthcare plan drugs or specialty pharmaceuticals are recent! Moderate through 2027 were conducted for specialty therapeutics at the FDA underline the industry...
specialty drug spend 2020 2021